Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Enrolling by invitation1
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

enrolling_by_invitation133%
terminated133%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitationphase_3

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

NCT04952610
completedphase_3

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

NCT05410860
terminatedphase_3

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

NCT03635996

Clinical Trials (3)

Showing 3 of 3 trials
NCT04952610Phase 3

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Enrolling By Invitation
NCT05410860Phase 3

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

Completed
NCT03635996Phase 3

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3